RemeGen has entered a licence agreement with Chinese compatriot Rongchang Pharmaceutical to obtain global exclusive rights to a pan-RAS(ON) small-molecule inhibitor programme, including lead compound RCZY-690, across all indications and uses. RemeGen will pay RMB 50 million (USD 7.5 million) upfront and up to RMB 4.87 billion (USD 730 million) in milestones, plus 3% to 7% tiered royalties on annual net sales, bringing a broadly mutant-selective RAS asset into its oncology portfolio.
Pan-RAS(ON) inhibitors aim to lock the active conformation of KRAS, NRAS and HRAS variants simultaneously, addressing the coverage gaps left by existing mutant-specific drugs in pancreatic, colorectal (CRC) and non-small-cell lung (NSCLC) cancers.
RCZY-690 already cleared clinical trial initiation in August and dosed its first patient in September, giving RemeGen a fast-starting solid-tumour programme.

Email us at pmc@pharmcube.com for a free database trial, exclusive reports, or a 1-on-1 consultation